Form D · Biotechnology
Solve Therapeutics, Inc.
Belmont, CA · CIK 0001905252
Offering snapshot reported Nov 25, 2025 · SEC filing
- Reported sold
- $48.2M Offering amount: $121M
- Investors reported
- 16 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 14, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 25, 2025 | Initial | $48,214,232 | No comparison | 16 | SEC filing |
| Dec 26, 2024 | Initial | $50,388,557 | No comparison | 10 | SEC filing |
| Jan 21, 2022 | Initial | $63,510,835 | No comparison | 11 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-564959
Source: Form D, filed Nov 25, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Peter Colabuono | Director |
| Alan Colowick | Director |
| David Johnson | Director, Executive |
| Clayton D. Knox | Executive |
| Daniel Mc Hugh | Director |
| Langdon Miller | Executive |
| Robert Mittendorff | Director |
| Jason Pitts | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1025 Alameda De Las Pulgas, Suite 122
Belmont, CA, 94002
Belmont, CA, 94002